Related Experiment Video

Updated: May 28, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth

Claudia Bocca1, Francesca Bozzo, Monica Ievolella

  • 1Department of Experimental Medicine and Oncology, University of Torino, Turin, Italy. claudia.bocca@unito.it

Molecular and Cellular Biochemistry
|October 18, 2011
PubMed

Insights

A novel rofecoxib analogue, NO-rofe, shows significant antiproliferative activity against colorectal cancer cells in vitro. This compound is more potent than rofecoxib and may offer a safer alternative for cancer research.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Rofecoxib, a COX-2 inhibitor, demonstrated antiproliferative effects on colorectal cancer but was withdrawn due to cardiovascular risks.
  • Despite market withdrawal, rofecoxib remains valuable for laboratory research as an experimental COX-2 inhibitor.

Purpose of the Study:

  • To investigate the in vitro antiproliferative activity of a novel dinitro-oxy-substituted rofecoxib analogue (NO-rofe) on human colon cancer cells.
  • To compare the efficacy of NO-rofe with rofecoxib, assessing COX-2 dependency and effects on the beta-catenin/E-cadherin pathway.

Main Methods:

  • In vitro experiments on COX-2-overexpressing (HT-29) and COX-2-negative (SW-480) human colon cancer cell lines.
  • Comparative analysis of NO-rofe and rofecoxib for antiproliferative activity and COX-2 inhibition.
  • Evaluation of the impact of COX-2 inhibition on the beta-catenin/E-cadherin signaling pathway.

Main Results:

  • NO-rofe exhibited significant antiproliferative activity on COX-2 positive HT-29 cells, with reduced efficacy on COX-2 negative SW-480 cells.
  • The rofecoxib analogue demonstrated comparable COX-2 inhibition potency but superior antiproliferative effects compared to rofecoxib in vitro.
  • NO-rofe induced membrane beta-catenin/E-cadherin expression, potentially contributing to its antiproliferative action.

Conclusions:

  • NO-rofe possesses potent in vitro antiproliferative activity against human colon cancer cells, particularly those overexpressing COX-2.
  • The novel analogue shows promise as a potentially less cardiotoxic COX-2 inhibitor for colorectal cancer research.
  • The observed effects suggest that NO-rofe's antiproliferative action may be linked to its influence on the beta-catenin/E-cadherin pathway.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...